HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
bis(D-gluconato-O1,O2)zink
Rubozinc · Zinc gluconat · Zinc dihexonate · zinc(ii) gluconate · bis(D-gluconato-O1,O2)zinc · rubozine · Aids002622 · Aids-002622
Identifikatoren & physikalische Daten
| CAS No. | 4468-02-4 |
|---|---|
| Summenformel | C12H22O14Zn |
| Durchschnittliche Molmasse | 455,7 g/mol |
| SMILES | O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Zn+2] |
| InChIKey | WHMDKBIGKVEYHS-IYEMJOQQSA-L |
| PubChem CID | 443445 |
| ChEMBL | CHEMBL3833377 |
| ChEBI | CHEBI:29708 |
| EC No. | 224-736-9 |
| DTXSID | DTXSID20894125 |
| Lokaler Name | bis(D-gluconato-O1,O2)zink |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 283 |
|---|---|
| H-Brücken-Donoren | 10 |
| H-Brücken-Akzeptoren | 14 |
| Frei drehbare Bindungen | 8 |
| Schwere Atome | 27 |
| Formalladung | 0 |
| Komplexität | 165 |
| Stoffklassen | Other Uses -> Food Additives |
| Kosmetika | Cosmetic ingredients (Zinc Gluconate) -> CIR (Cosmetic Ingredient Review)Skin conditioningDeodorant |
| Lebensmittelzusatzstoffe | NUTRIENT SUPPLEMENT -> FDA Substance added to food |
| Color/Form | Powder or granular |
| Löslichkeit | moderately solubleSoluble in water, practically insoluble in anhydrous ethanol and in methylene chloride.Soluble in water 100g/ l. |
| Animal Drugs | Active Ingredients (Zinc Gluconate) -> FDA Greenbook |
| Physical Description | Solid[HSDB] White granular solid[MSDSonline] |
| Schmelzpunkt | 172-175 °C |
| Siedepunkt | 319°C |
| Dichte | 1.44[at 20℃] |
| Dampfdruck | 0Pa at 20℃ |
| Lagerbedingungen | Store at -20°C |
| Aggregatzustand | powder to crystal |
| Farbe | White to Almost white |
| Merck | 14,4456 |
| Kosmetik-Inhaltsstoffe Funktionen | ORAL CAREANTIMICROBIALSKIN CONDITIONINGDEODORANT |
| InChI | InChI=1/2C6H12O7.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13/h2*2-5,7-11H,1H2,(H,12,13)/q+2/p-2/t2*2-,3-,4+,5-/s3 |
| InChIKey | WHMDKBIGKVEYHS-ATBKJFGMNA-L |
| SMILES | [C@H](O)([C@H](O)[C@H](O)CO)[C@@H](O)C(=O)O[Zn]OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |&1:0,2,4,8,17,19,21,23,r| |
| LogP (Verteilungskoeffizient) | -7.41 at 20℃ |
| CAS Datenbank | 4468-02-4(CAS DataBase Reference) |
| EPA chemische Informationen | Zinc, bis(D-gluconato-.kappa.O1,.kappa.O2)-, (T-4)- (4468-02-4) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 14.7% (39 of 266) of reports.DangerH318 (81.6%): Causes serious eye damage [Danger Serious eye damage/eye irritation]P264+P265, P273, P280, P305+P354+P338, P317, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 266 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Chemical: Zinc, bis(D-gluconato-.kappa.O1,.kappa.O2)-, (T-4)-Status: Active Update: 20-12-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24253Zinc, bis(D-gluconato-.kappa.O1,.kappa.O2)-, (T-4)-: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | IMAP assessments - Zinc, bis(D-gluconato-O1,O2)-: Human health tier I assessment |
| Gefahrenübersicht | Generally regarded as safe (GRAS) for use as dietary supplement and nutrient[HSDB] At oral doses of 47 mg/kg, volunteers complained of distorted perceptions and nausea or vomitingIntravenous LD50 (mouse) = 23.7 mg/kgOral LD50 (mouse) = 1290 mg/kg[ChemIDplus] May cause irritation[MSDSonline] See Zinc. |
| FDA-Anforderungen | This substance is generally recognized as safe when used as a nutrient and/or dietary supplement in accordance with good manufacturing or feeding practice. |
| Special Reports | Zinc and Health. Current Bibliographies in Medicine 98-3. Public Services Division/National Library of Medicine. 3619 citations January, 1990-June, 1998. Available from: http://www.nlm.nih.gov/archive/20040831/pubs/cbm/zinc.html as of November 2, 1998.USEPAAmbient Water Quality Criteria Doc: Zinc (1980) EPA 400/5-80-079Ambient Water Quality Criteria Doc: Zinc (1987) EPA 400/5-87-003Arvidson, B. A Review of Axonal Transport of Metals. Toxicology 88: 1-14 (19994) Recent findings regarding axonal transport of metals, including zinc.For more Special Reports (Complete) data for ZINC GLUCONATE (6 total), please visit the HSDB record page. |
| Clean Water Act Anforderungen | Toxic pollutant designated pursuant to section 307(a)(1) of the Clean Water Act and is subject to effluent limitations. /Zinc and compounds/For total recoverable zinc the criterion-to protect freshwater aquatic life ... is 47 ng/l as a 24 hr average ... at hardnesses of 50, 100, and 200 mg/l as CaCO3 the concentration of total recoverable zinc should not exceed 180, 320, 570 ug/l at any time. /Soluble zinc salts/For total recoverable zinc the criterion to protect saltwater aquatic life ... is 58 ug/l as a 24 hr average and the concentration should not exceed 170 ug/l at any time. /Soluble zinc salts/ |
| Hazard Classes and Categories | Eye Dam. 1 (81.6%) |
| Landesrichtlinien für Trinkwasser | (AZ) ARIZONA 5000 ug/l /Zinc/(MN) MINNESOTA 2000 ug/l /Zinc/ |
| Bundesrichtlinien für Trinkwasser | EPA 5000 ug/l /Zinc/EPA 2000 ug/l /Zinc, Lifetime health advisory/ |
| Entsorgungsverfahren | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
| Minimum Risk Level | Intermediate Oral: 0.3 mg/kg/day (L134) Chronic Oral: 0.3 mg/kg/day (L134) |
| Treatment | Zinc poisoning is treated symptomatically, often by administering fluids such as water or milk, or with gastric lavage. (L49) |
| Wechselwirkungen | Large doses of zinc may inhibit copper absorption in the intestinezinc supplements should be taken at least 2 hours after the administration of copper supplements. /Zinc supplements/Thiazide diuretics have been found to increase urinary zinc excretion. /Zinc supplements/Concurrent use of large amounts of fiber, phosphorus, or phytates with zinc supplements may reduce zinc absorption by formation of nonabsorbable complexesfood containing fiber, phosphorus, or phytates should be taken at least 2 hours after zinc supplements. /Zinc supplements/Some studies have found that folate can decrease the absorption of zinc, but not in the presence of excessive zincother studies have found no inhibition. /Zinc supplements/For more Interactions (Complete) data for ZINC GLUCONATE (8 total), please visit the HSDB record page. |
| Gesundheitliche Auswirkungen | Chronic exposure to zinc causes anemia, atazia, lethargy, and decreases the level of good cholesterol in the body. It is also believed to cause pancreatic and reproductive damage. (L49) |
| Expositionspfade | Inhalation (L49)oral (L49)dermal (L49) |
| Toxizitätsübersicht | The CIR Expert Panel concluded that the following 27 zinc salts are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-irritating...Zinc Gluconate...Safe for use in cosmetics, with qualificationsAnaemia results from the excessive absorption of zinc suppressing copper and iron absorption, most likely through competitive binding of intestinal mucosal cells. Unbalanced levels of copper and zinc binding to Cu,Zn-superoxide dismutase has been linked to amyotrophic lateral sclerosis (ALS). Stomach acid dissolves metallic zinc to give corrosive zinc chloride, which can cause damage to the stomach lining. Metal fume fever is thought to be an immune response to inhaled zinc. (L48, L49, A49) |
| Signs and Symptoms | Ingestion of large doses of zinc causes stomach cramps, nausea, and vomiting. Acute inhalation of large amounts of zinc causes metal fume fever, which is characterized by chills, fever, headache, weakness, dryness of the nose and throat, chest pain, and coughing. Dermal contact with zinc results in skin irritation. (L49) |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Probable Routes of Human Exposure | Use of zinc gluconate in therapeutic applications will result in exposure in humans. Its use in cold remedies will result in considerable oral exposure in humans. (SRC) |
| TSCA-Inventar-Status | TSCA listed |
| Zollcode | 29181600 |
| RTECS-Nr. | ZH3750000 |
| Gefahrstoffdaten | 4468-02-4(Hazardous Substances Data) |
Anwendungen & Verwendung
Verwenden
zinc gluconate helps maintain the skin in good condition and acts as a deodorant by preventing the growth of micro-organisms, such as bacteria, fungi or yeast, in a formulation. Zinc gluconate could also be effectively used in anti-acne products.